The founder and CEO of Joi Wellness Group Multiple Sclerosis Center described motivations behind the evaluation of ocrelizumab (Ocrevus; Genentech) in minority populations with multiple sclerosis.
Mitzi Joi Williams, MD
Advertisement
Board-certified neurologist and multiple sclerosis specialist; founder and CEO, Joi Life Wellness Group Multiple Sclerosis Center
Articles by Mitzi Joi Williams, MD
Outlining the development of the CHIMES trial in multiple sclerosis, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke on tactics to get underrepresented populations involved. [WATCH TIME: 2 minutes]
The founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center outlined the motivations behind the trial, as well as potential reasons for underrepresentation. [WATCH TIME: 2 minutes]
As the MS patient population includes more patients from the millennial generation, the founder and CEO of the Joi Life Wellness Group Multiple Sclerosis Center offered her insight on the way care differs for this generation compared with prior ones. [WATCH TIME: 4 minutes]
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
POLARIS-AD Phase 3 Trial of PDE5 Inhibitor AR1001 Completes Treatment Phase With Favorable Safety Profile
2
FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea
3
Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease
4
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment
5